DLC-1, a candidate tumor suppressor gene, inhibits the proliferation, migration and tumorigenicity of human nasopharyngeal carcinoma cells

Feng,Xiangling; Li,Cui; Liu,Weidong; Chen,Huan; Zhou,Wen; Wang,Lei; Zhu,Bin; Yao,Kaitai; Jiang,Xingjun; Ren,Caiping

doi:10.3892/ijo.2013.1885

DLC-1, a candidate tumor suppressor gene, inhibits the proliferation, migration and tumorigenicity of human nasopharyngeal carcinoma cells

Authors:
- Xiangling Feng
- Cui Li
- Weidong Liu
- Huan Chen
- Wen Zhou
- Lei Wang
- Bin Zhu
- Kaitai Yao
- Xingjun Jiang
- Caiping Ren
View Affiliations

Affiliations: Cancer Research Institute, Xiang-Ya School of Medicine, Central South University, Key Laboratory for Carcinogenesis of Chinese Ministry of Health, Key Laboratory for Carcinogenesis and Cancer Invasion of Chinese Ministry of Education, Changsha, Hunan 410078, P.R. China, Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Hunan 410008, P.R. China, Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: April 8, 2013 https://doi.org/10.3892/ijo.2013.1885
Pages: 1973-1984

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In our previous study we demonstrated the downregulation or loss of deleted in liver cancer‑1 (DLC-1) gene expression in nasopharyngeal carcinoma (NPC). In this study, we report the effects of the DLC-1 gene on NPC cells and its mechanisms of action. DLC-1 expression was restored in the 5-8F NPC cell line, which lacks DLC-1 expression, and the biological characteristics of 5-8F-DLC‑1 cells were analyzed by MTT assay, colony formation assay, flow cytometry (FCM), tumorigenesis analysis in nude mice, as well as invasion and migration assay. Differentially expressed genes in response to DLC-1 expression were screened using microarray analysis and identified by RT-PCR. The re-expression of DLC-1 in the NPC cells attenuated the proliferation and colony formation ability of the cells in vitro, blocked NPC cells at the G0/G1 phase, reduced tumorigenicity potential in vivo, inhibited the invasion and migration ability of NPC cells and resulted in the reorganization of the actin cytoskeleton. DLC-1 altered the gene expression profile in 5-8F cells. Some tumor suppressor genes (TSGs) were upregulated and some oncogenes were downregulated. These results demonstrate that DLC-1 gene can partially reverse the malignant phenotype of NPC cells by changing the tumor-related gene expression profile, and may be a candidate tumor suppressor gene and a promising diagnostic and therapeutic target in NPC.

View Figures

View References

1	Chang ET and Adami HO: The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 15:1765–1777. 2006. View Article : Google Scholar : PubMed/NCBI
2	Yao KT: The application and prospect of nasopharyngeal carcinoma etiology. China Cancer. 6:3–4. 1997.
3	Lo KW, To KF and Huang DP: Focus on nasopharyngeal carcinoma. Cancer Cell. 5:423–428. 2004. View Article : Google Scholar : PubMed/NCBI
4	Wei WI and Sham JS: Nasopharyngeal carcinoma. Lancet. 365:2041–2054. 2005. View Article : Google Scholar : PubMed/NCBI
5	Tao Q and Chan AT: Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med. 9:1–24. 2007.PubMed/NCBI
6	Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS and Popescu NC: Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res. 58:2196–2199. 1998.PubMed/NCBI
7	Durkin ME, Yuan BZ, Zhou X, et al: DLC-1: a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med. 11:1185–1207. 2007. View Article : Google Scholar : PubMed/NCBI
8	Lahoz A and Hall A: DLC-1: a significant GAP in the cancer genome. Genes Dev. 22:1724–1730. 2008. View Article : Google Scholar : PubMed/NCBI
9	Peng D, Ren CP, Yi HM, et al: Genetic and epigenetic alterations of DLC-1, a candidate tumor suppressor gene, in nasopharyngeal carcinoma. Acta Biochim Biophys Sin (Shanghai). 38:349–355. 2006. View Article : Google Scholar : PubMed/NCBI
10	Seng TJ, Low JS, Li H, et al: The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene. 26:934–944. 2007. View Article : Google Scholar
11	Zhang H, Feng X, Liu W, et al: Underlying mechanisms for LTF inactivation and its functional analysis in nasopharyngeal carcinoma cell lines. J Cell Biochem. 112:1832–1843. 2011. View Article : Google Scholar : PubMed/NCBI
12	Zhou W, Feng X, Li H, et al: Functional evidence for a nasopharyngeal carcinoma-related gene BCAT1 located at 12p12. Oncol Res. 16:405–413. 2007.PubMed/NCBI
13	Shao JY, Wang HY, Huang XM, et al: Genome-wide allelotype analysis of sporadic primary nasopharyngeal carcinoma from southern China. Int J Oncol. 17:1267–1275. 2000.PubMed/NCBI
14	Song L and Wang H: Study on the tumor heterogeneity of nasopharyngeal carcinoma cell line (SUNE-1). Chin J Cancer. 17:324–327. 1998.
15	Kim TY, Lee JW, Kim HP, et al: DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. Biochem Biophys Res Commun. 355:72–77. 2007. View Article : Google Scholar : PubMed/NCBI
16	Wong CM, Yam JW, Ching YP, et al: Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res. 65:8861–8868. 2005. View Article : Google Scholar : PubMed/NCBI
17	Goodison S, Yuan J, Sloan D, et al: The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res. 65:6042–6053. 2005. View Article : Google Scholar : PubMed/NCBI
18	Yuan BZ, Jefferson AM, Millecchia L, Popescu NC and Reynolds SH: Morphological changes and nuclear translocation of DLC1 tumor suppressor protein precede apoptosis in human non-small cell lung carcinoma cells. Exp Cell Res. 313:3868–3880. 2007. View Article : Google Scholar : PubMed/NCBI
19	Ullmannova-Benson V, Guan M, Zhou X, et al: DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway. Leukemia. 23:383–390. 2009. View Article : Google Scholar : PubMed/NCBI
20	Loyo M, Brait M, Kim MS, et al: A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. Int J Cancer. 128:1393–1403. 2011. View Article : Google Scholar : PubMed/NCBI
21	Li G, Du X, Vass WC, Papageorge AG, Lowy DR and Qian X: Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK). Proc Natl Acad Sci USA. 108:17129–17134. 2011. View Article : Google Scholar : PubMed/NCBI
22	Qian X, Li G, Asmussen HK, et al: Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci USA. 104:9012–9017. 2007. View Article : Google Scholar
23	Liao YC, Si L, deVere White RW and Lo SH: The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J Cell Biol. 176:43–49. 2007. View Article : Google Scholar : PubMed/NCBI
24	Yam JW, Ko FC, Chan CY, Jin DY and Ng IO: Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res. 66:8367–8372. 2006. View Article : Google Scholar : PubMed/NCBI
25	Hall EH, Balsbaugh JL, Rose KL, Shabanowitz J, Hunt DF and Brautigan DL: Comprehensive analysis of phosphorylation sites in Tensin1 reveals regulation by p38MAPK. Mol Cell Proteomics. 9:2853–2863. 2010. View Article : Google Scholar : PubMed/NCBI
26	Deng YF, Zhou DN, Ye CS, Zeng L and Yin P: Aberrant expression levels of MTA1 and RECK in nasopharyngeal carcinoma: association with metastasis, recurrence, and prognosis. Ann Otol Rhinol Laryngol. 121:457–465. 2012. View Article : Google Scholar : PubMed/NCBI
27	Meng N, Li Y, Zhang H and Sun XF: RECK, a novel matrix metalloproteinase regulator. Histol Histopathol. 23:1003–1010. 2008.PubMed/NCBI
28	Noda M, Oh J, Takahashi R, Kondo S, Kitayama H and Takahashi C: RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev. 22:167–175. 2003. View Article : Google Scholar : PubMed/NCBI
29	Rohan PJ, Davis P, Moskaluk CA, et al: PAC-1: a mitogen-induced nuclear protein tyrosine phosphatase. Science. 259:1763–1766. 1993. View Article : Google Scholar : PubMed/NCBI
30	Zhang Q, Muller M, Chen CH, Zeng L, Farooq A and Zhou MM: New insights into the catalytic activation of the MAPK phosphatase PAC-1 induced by its substrate MAPK ERK2 binding. J Mol Biol. 354:777–788. 2005. View Article : Google Scholar : PubMed/NCBI
31	Lin SC, Chien CW, Lee JC, et al: Suppression of dual-specificity phosphatase-2 by hypoxia increases chemoresistance and malignancy in human cancer cells. J Clin Invest. 121:1905–1916. 2011. View Article : Google Scholar : PubMed/NCBI
32	Ruan L, Li XH, Wan XX, et al: Analysis of EGFR signaling pathway in nasopharyngeal carcinoma cells by quantitative phosphoproteomics. Proteome Sci. 9:352011. View Article : Google Scholar : PubMed/NCBI
33	Wan Y, Yang M, Kolattukudy S, Stark GR and Lu T: Activation of cAMP-responsive-element-binding protein by PI3 kinase and p38 MAPK is essential for elevated expression of transforming growth factor beta2 in cancer cells. J Interferon Cytokine Res. 30:677–681. 2010. View Article : Google Scholar : PubMed/NCBI
34	Tanioka Y, Yoshida T, Yagawa T, et al: Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer. 89:2116–2121. 2003. View Article : Google Scholar : PubMed/NCBI
35	Koskensalo S, Louhimo J, Nordling S, Hagstrom J and Haglund C: MMP-7 as a prognostic marker in colorectal cancer. Tumour Biol. 32:259–264. 2011. View Article : Google Scholar : PubMed/NCBI
36	Koskensalo S, Mrena J, Wiksten JP, et al: MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol. 31:149–155. 2010. View Article : Google Scholar : PubMed/NCBI
37	Awakura Y, Nakamura E, Takahashi T, et al: Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma. J Cancer Res Clin Oncol. 134:1363–1369. 2008. View Article : Google Scholar : PubMed/NCBI
38	Ikeda J, Oda T, Inoue M, et al: Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Sci. 100:429–433. 2009. View Article : Google Scholar : PubMed/NCBI
39	Uekita T, Jia L, Narisawa-Saito M, Yokota J, Kiyono T and Sakai R: CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol. 27:7649–7660. 2007. View Article : Google Scholar : PubMed/NCBI
40	Chou J, Lin YC, Kim J, et al: Nasopharyngeal carcinoma - review of the molecular mechanisms of tumorigenesis. Head Neck. 30:946–963. 2008. View Article : Google Scholar : PubMed/NCBI
41	Tulalamba W and Janvilisri T: Nasopharyngeal carcinoma signaling pathway: an update on molecular biomarkers. Int J Cell Biol. 2012:5946812012. View Article : Google Scholar : PubMed/NCBI
42	Dang CV: Links between metabolism and cancer. Genes Dev. 26:877–890. 2012. View Article : Google Scholar : PubMed/NCBI